Sulfasalazine-Induced Epstein-Barr Virus-Positive Mucocutaneous Ulcer.
Journal
Case reports in hematology
ISSN: 2090-6560
Titre abrégé: Case Rep Hematol
Pays: United States
ID NLM: 101576456
Informations de publication
Date de publication:
2024
2024
Historique:
received:
29
03
2024
revised:
17
05
2024
accepted:
29
05
2024
medline:
10
7
2024
pubmed:
10
7
2024
entrez:
10
7
2024
Statut:
epublish
Résumé
Epstein-Barr virus (EBV) may cause a wide spectrum of symptomatology in humans ranging from asymptomatic upper respiratory tract infection to infectious mononucleosis and in more severe cases lymphoproliferative disorders or hemophagocytic lymphohistiocytosis. Its neoplastic potential is higher in immunocompromised individuals. We describe a case of EBV-positive mucocutaneous ulcer, a more indolent clinical entity on the spectrum of EBV-driven lymphoproliferative disorders, and are one of the first to put sulfasalazine, an immunomodulatory agent, forward as the possible culprit.
Identifiants
pubmed: 38983901
doi: 10.1155/2024/6883657
pmc: PMC11233183
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Pagination
6883657Informations de copyright
Copyright © 2024 Cedric Stabel et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.